IDEXX Laboratories, Inc.
American multinational corporation
IDXX Nasdaq
ISIN US45168D1046 SEC CIK 874716 LEI OGMTXK0LUU1HKV2P0J84
Follow IDEXX Laboratories
Weekly email: filings, results
Revenue, last quarter
$1.2B
+9.9% vs same quarter last year
Net income
$317.1M
+15.5% vs same quarter last year
EPS, diluted
$4.01
+17.9% vs same quarter last year
Operating cash flow
$449.7M
+11.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $4.3B | $1.1B |
| FY24 | $3.9B | $887.9M |
| FY23 | $3.7B | $845M |
| FY22 | $3.4B | $679.1M |
| FY21 | $3.2B | $744.8M |
| FY20 | $2.7B | $581.8M |
| FY19 | $2.4B | $427.7M |
| FY18 | $2.2B | $377M |
| FY17 | $2B | $263.1M |
| FY16 | $1.8B | $222M |
| FY15 | $1.6B | $192.1M |
| FY14 | $1.5B | $181.9M |
| FY13 | $1.4B | $187.8M |
| FY12 | $1.3B | $178.3M |
| FY11 | $1.2B | $161.8M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 61.8% | 31.6% | 24.6% |
| FY24 | 61% | 29% | 22.8% |
| FY23 | 59.8% | 30% | 23.1% |
| FY22 | 59.5% | 26.7% | 20.2% |
| FY21 | 58.8% | 29% | 23.2% |
| FY20 | 58% | 25.7% | 21.5% |
| FY19 | 56.7% | 23% | 17.8% |
| FY18 | 56.1% | 22.2% | 17% |
| FY17 | 55.7% | 21% | 13.4% |
| FY16 | 54.9% | 19.7% | 12.5% |
| FY15 | 55.6% | 18.7% | 12% |
| FY14 | 54.9% | 17.5% | 12.2% |
| FY13 | 54.9% | 19.4% | 13.6% |
| FY12 | 54.1% | 20.3% | 13.8% |
| FY11 | 53% | 19.4% | 13.3% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $1.1B |
| FY24 | $808.1M |
| FY23 | $772.9M |
| FY22 | $394.1M |
| FY21 | $636M |
| FY20 | $541.1M |
| FY19 | $304.2M |
| FY18 | $284.3M |
| FY17 | $298.9M |
| FY16 | $274.2M |
| FY15 | $138.9M |
| FY14 | $175.3M |
| FY13 | $168.4M |
| FY12 | $164.8M |
| FY11 | $168.2M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $1.2B |
| FY24 | $837M |
| FY23 | $71.9M |
| FY22 | $819.7M |
| FY21 | $746.8M |
| FY20 | $182.8M |
| FY19 | $301.7M |
| FY18 | $369.3M |
| FY17 | $282.6M |
| FY16 | $304.1M |
| FY15 | $402M |
| FY14 | $618.2M |
| FY13 | $367.8M |
| FY12 | $132.3M |
| FY11 | $255.5M |
- IDEXX Laboratories
- Healthcare median
Show the numbers
| Year | IDEXX Laboratories | Healthcare median |
|---|---|---|
| FY25 | 24.6% | −30.6% |
| FY24 | 22.8% | −47% |
| FY23 | 23.1% | −58% |
| FY22 | 20.2% | −80.4% |
| FY21 | 23.2% | −71.9% |
| FY20 | 21.5% | −62.2% |
| FY19 | 17.8% | −46.3% |
| FY18 | 17% | −49.6% |
| FY17 | 13.4% | −45.9% |
| FY16 | 12.5% | −36% |
| FY15 | 12% | −38.4% |
| FY14 | 12.2% | −35.5% |
| FY13 | 13.6% | −37.1% |
| FY12 | 13.8% | −29.1% |
| FY11 | 13.3% | −27.9% |